Patents by Inventor Matthew W. KALNIK

Matthew W. KALNIK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL NICOTINE DEGRADING ENZYME VARIANTS
    Publication number: 20230416697
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.
    Type: Application
    Filed: March 2, 2023
    Publication date: December 28, 2023
    Applicants: Antidote Therapeutics, Inc., Board of Regents, The University of Texas System
    Inventors: Matthew W. KALNIK, Thomas THISTED, Everett STONE, Charles C. REED, Max RODNICK-SMITH
  • NOVEL NICOTINE-BINDING ANTIBODIES
    Publication number: 20230089068
    Abstract: Described are novel nicotine-binding antibodies and methods of using them for treating nicotine addiction and/or facilitating smoking cessation, or for treating nicotine overdose or nicotine poisoning.
    Type: Application
    Filed: August 12, 2022
    Publication date: March 23, 2023
    Applicants: ANTIDOTE THERAPEUTICS, INC., BliNK BIOMEDICAL, Hennepin Healthcare Research Institute
    Inventors: Matthew W. KALNIK, Thomas THISTED, Nicola BELTRAMINELLI, Stéphanie FALLOT, Zuzana BIESOVA, Steve FULLER, Mark G. LeSAGE, Paul PENTEL
  • Nicotine degrading enzyme variants
    Patent number: 11597916
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 7, 2023
    Assignees: ANTIDOTE THERAPEUTICS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Matthew W. Kalnik, Thomas Thisted, Everett Stone, Charles C. Reed, Max Rodnick-Smith
  • Nicotine-binding antibodies
    Patent number: 11440970
    Abstract: Described are novel nicotine-binding antibodies and methods of using them for treating nicotine addiction and/or facilitating smoking cessation, or for treating nicotine overdose or nicotine poisoning.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: September 13, 2022
    Assignees: ANTIDOTE THERAPEUTICS, INC., BliNK BIOMEDICAL, Hennepin Healthcare Research Institute
    Inventors: Matthew W. Kalnik, Thomas Thisted, Nicola Beltraminelli, Stéphanie Fallot, Zuzana Biesova, Steve Fuller, Mark G. Lesage, Paul Pentel
  • METHODS FOR IMPROVING CIRCULATION AND TREATING CARDIOVASCULAR DISEASE
    Publication number: 20220267474
    Abstract: Described are methods of treating cardiovascular diseases in smokers and/or subjects ingesting or consuming nicotine from other sources (e-cigarettes/vaping, smokeless tobacco, NRT, etc.
    Type: Application
    Filed: June 5, 2019
    Publication date: August 25, 2022
    Applicant: ANTIDOTE THERAPEUTICS, INC.
    Inventors: Matthew W. KALNIK, Thomas THISTED, Warren C. STERN
  • NOVEL NICOTINE DEGRADING ENZYME VARIANTS
    Publication number: 20220031814
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 enzyme, compositions comprising the variants, and methods using them.
    Type: Application
    Filed: July 2, 2019
    Publication date: February 3, 2022
    Applicant: ANTIDOTE THERAPEUTICS, INC.
    Inventors: Matthew W. KALNIK, Thomas THISTED, Charles C. REED
  • NOVEL NICOTINE-BINDING ANTIBODIES
    Publication number: 20200377616
    Abstract: Described are novel nicotine-binding antibodies and methods of using them for treating nicotine addiction and/or facilitating smoking cessation, or for treating nicotine overdose or nicotine poisoning.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 3, 2020
    Applicants: ANTIDOTE THERAPEUTICS, INC., BliNK BIOMEDICAL, Hennepin Healthcare Research Institute
    Inventors: Matthew W. KALNIK, Thomas THISTED, Nicola BELTRAMINELLI, Stéphanie FALLOT, Zuzana BIESOVA, Steve FULLER, Mark G. LESAGE, Paul PENTEL
  • NOVEL NICOTINE DEGRADING ENZYME VARIANTS
    Publication number: 20200224176
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.
    Type: Application
    Filed: February 2, 2018
    Publication date: July 16, 2020
    Applicants: ANTIDOTE THERAPEUTICS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Matthew W. KALNIK, Thomas THISTED, Everett STONE, Charles C. REED, Max RODNICK-SMITH